glp-1 side effect lawsuit in kentucky Some podiatrists are voicing concerns about a new known as "Ozempic feet." More information on the condition is available here: https://fox59.com/news/national-world/ozempic-feet-the-latest-side-effect -among-glp-1-users-doctors-warn Ozempic Lawsuit | Ohio and

This could include non-invasive neuromodulation techniques (e.g., transcutaneous auricular vagus nerve stimulation), pharmacological enhancement of endogenous GLP-1 release from L-cells, or dietary manipulations designed to optimize postprandial incretin release [39,40]

Many of these patients have turned to a compounded alternative

This combination of delayed digestion and drier stool creates the perfect conditions for constipation

Ozempic (aka

The growth of GLP-1 use has also led to early acquisitions: in 2023, Weight Watchers acquired Sequence, a Series A telehealth company that prescribes GLP-1 drugs and provides support comprehensive services, for $132M

Umpierrez GE, Cardona S, Chachkhiani D et al (2018) A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC trial